DekaBank Deutsche Girozentrale Decreases Stake in Hologic, Inc. $HOLX

DekaBank Deutsche Girozentrale reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 5.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,475,379 shares of the medical equipment provider’s stock after selling 82,661 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.66% of Hologic worth $96,123,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Chung Wu Investment Group LLC purchased a new position in Hologic in the 2nd quarter valued at about $26,000. Zions Bancorporation National Association UT purchased a new position in Hologic in the 1st quarter valued at about $34,000. Cromwell Holdings LLC boosted its position in Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 436 shares during the last quarter. Allworth Financial LP boosted its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Hologic in the 1st quarter valued at about $42,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.88% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HOLX. UBS Group upped their target price on shares of Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Mizuho set a $75.00 target price on shares of Hologic in a research note on Thursday, July 31st. Wall Street Zen lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Hologic in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.15.

Hologic Price Performance

HOLX opened at $71.87 on Tuesday. The firm has a market cap of $15.99 billion, a price-to-earnings ratio of 29.82, a price-to-earnings-growth ratio of 2.40 and a beta of 0.63. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company’s 50-day moving average price is $67.19 and its 200 day moving average price is $63.62. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.